UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000024286
Receipt number R000026696
Scientific Title Neural mechanism of voice processing in autism spectrum disorder and schizophrenia
Date of disclosure of the study information 2016/10/04
Last modified on 2019/10/29 10:04:58

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Neural mechanism of voice processing in autism spectrum disorder and schizophrenia

Acronym

Voice processing in ASD and schizophrenia

Scientific Title

Neural mechanism of voice processing in autism spectrum disorder and schizophrenia

Scientific Title:Acronym

Voice processing in ASD and schizophrenia

Region

Japan


Condition

Condition

Autism spectrum disorder
Schizophrenia

Classification by specialty

Psychiatry

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To clarify neural network in processing of human voice in ASD and Schizophrenia by using fMRI

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

fMRI, psychological tests

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Diagnosis

Type of intervention

Device,equipment

Interventions/Control_1

Individuals with autism spectrum disorder

Interventions/Control_2

individuals with schizophrenia

Interventions/Control_3

Normal controls

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

50 years-old >

Gender

Male and Female

Key inclusion criteria

Individuals with autism spectrum disorder:
1) Individuals who is diagnosed as autism spectrum disorder based on DSM-V
2) Individuals who do not have any other neurological or psychiatric disorders
3) Individuals whose IQs are more than 80, and who have capability of informed consent

Individuals with schizophrenia:
1) Individuals who is diagnosed as schizophrenia based on DSM-V
2) Individuals who do not have any other neurological or psychiatric disorders
3) Individuals who have capability of informed consent

Normal controls
1) Individuals who do not have no neurological or psychiatric disorders
2) Individuals whose estimated IQs are more than 80, and who have capability of informed consent

Key exclusion criteria

Individuals with autism spectrum disorder (ASD) and normal controls
1) with implanted cardiac pacemaker
2) with surgical aneurysm clips
3) with neurostimulator
4) with implanted pumps
5) with metal fragments in body
6) with tattoos, permanent eyeliner (if ink contains metallic specks)
7) with pregnancy and at risk of becoming pregnant
8) Subjects who are judged as unsuitable for participation in this study by their primary doctor (individuals with ASD only)

Target sample size

90


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Nobumasa Kato

Organization

Showa University

Division name

Medical Institute of Developmental Disabilities Research

Zip code


Address

6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo

TEL

03-3300-5231

Email

katon@med.showa-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Rieko Okada

Organization

Showa University

Division name

Medical Institute of Developmental Disabilities Research

Zip code


Address

6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo

TEL

03-3300-5231

Homepage URL


Email

rokada@med.showa-u.ac.jp


Sponsor or person

Institute

Medical Institute of Developmental Disabilities Research, Showa University

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 10 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 07 Month 01 Day

Date of IRB

2016 Year 01 Month 26 Day

Anticipated trial start date

2016 Year 09 Month 30 Day

Last follow-up date

2018 Year 09 Month 28 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 10 Month 04 Day

Last modified on

2019 Year 10 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026696


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name